Oct 4, 2022

Sigyn Therapeutics outlines first-in-human clinical strategy for its novel blood purification technology

Apr 26, 2022

Sigyn Therapeutics Names Hepatology Leader Dr. Donald Hillebrand to SAB

Apr 7, 2022

New Sigyn CFO Maps Nasdaq Uplist, Shelf Registration Strategy

Mar 31, 2022

Sigyn Therapeutics Names Neurology Leader Dr. Ajay Verma to SAB

Mar 30, 2022

Cytokine Storm: The Unmet Need Sigyn Hopes To Address

Mar 15, 2022

Sigyn Therapeutics Names Leading Nephrologist Dr. H. David Humes to SAB

Mar 9, 2022

Sigyn Appoints Internationally Recognized Nephrologist Dr. Alexander Yevzlin to SAB

Feb 25, 2022

BioTech IQ:Treatments that can reach beyond on the function of drugs? James Joyce, CEO - Sigyn Therapeutics

Feb 23, 2022

Biotech Tuesdays: Sigyn Therapeutics completes animal studies; Sigyn Therapy safe and well tolerated

Feb 15, 2022

Sigyn Therapeutics hopes to file IDE in Q2 for human studies of Sigyn Therapy